Dr Glenn Noronha has over 20 years of progressive leadership and research experience across small and large biotechnology and pharmaceutical companies. He was successful in developing, implementing and executing drug development strategy, and creating successful business as well as research and development roadmaps.
Based in the US, Dr Noronha has deep expertise in development of ophthalmology drug candidates through his positions at BridgeBio Pharma, Clearside Biomedical and Alcon, formerly the ophthalmology subsidiary of Novartis. In February 2021, he was appointed chief development officer of ASX-listed PYC Therapeutics, a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases. He will oversee the company’s translational clinical development, regulatory, manufacturing and preclinical development activities as it advances its pipeline of multiple drug candidates which is initially focused on inherited ocular diseases.
Dr Noronha has been involved in 8 Investigational New Drug applications, and 3 New Drug Applications with the US Food and Drug Administration.
